nach oben

Digestive Diseases and Sciences

Erschienen in:

20.05.2019 | UNM CLINICAL CASE CONFERENCES

A Granular Approach to a Patient with Diarrhea and Flushing

verfasst von: Anas Gremida, Fazia Mir, Denis McCarthy

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 57-year-old male was initially evaluated for a 3-month history of diarrhea and flushing. His diarrhea was of small volume with a Bristol stool scale 6–7. He had 5–6 bowel movements daily, mostly diurnal with rare nocturnal events, associated with generalized abdominal cramping and nausea, usually occurring 5–10 min after food ingestion, and aggravated by exposure to heat or hot showers. His symptoms were associated with dizziness, nausea, and sense of flushing. The patient denied tenesmus, dyschezia, or hematochezia. Over the 3-month period, the frequency of diarrhea increased, accompanied by intensified abdominal cramps. …

Gilfillan AM, Austin SJ, Metcalfe DD. MC biology: introduction and overview. Adv Exp Med Biol. 2011;716:2–12.CrossRefPubMedPubMedCentral

Krishnaswamy G, Kelley J, Johnson D, Youngberg G, et al. The human mast cell: functions in physiology and disease. Front Biosci. 2001;6:1109–11027.CrossRef

Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immune Res. 2006;34:97–115.CrossRef

Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol. 2012;3:238.CrossRefPubMedPubMedCentral

Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. 1999;31:1037–1051.CrossRefPubMed

Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–220.CrossRefPubMed

Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. Cell Mol Life Sci. 2011;6:965–975.CrossRef

Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004;59:695–703.CrossRefPubMed

Lawrence JB, Friedman BS, Travis WD, Chinchilli VM. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91:612–624.CrossRefPubMed

10.

Arock M. Mastocytosis, classification, biological diagnosis and therapy. Ann Biol Clin. 2004;62:657–669.

11.

Ertugrul A, Bostanci I, Ozturk Kaymak A, Gurkan A. Pediatric cutaneous mastocytosis and c-KIT mutation screening. Allergy Asthma Proc. 2019;40:123–128.CrossRefPubMed

12.

Lim KH, Tefferi A, Lasho TL, Finke C, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–5736.CrossRefPubMed

13.

Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006;147:127–135.CrossRef

14.

Togias A. H1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol. 2003;112:60–68.CrossRef

15.

Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183–1241.CrossRefPubMed

16.

Thrumond R. The histamine H₄ receptor: from orphan to the clinic. Front Pharmacol. 2015;6:65.

17.

He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des. 2013;19:1114–1125.CrossRefPubMedPubMedCentral

18.

Martins C, Teixeira C, Ribeiro S, Trabulo D, et al. Systemic mastocytosis: a rare cause of non-cirrhotic portal hypertension. World J Gastroenterol. 2016;22:6559–6564.CrossRefPubMedPubMedCentral

19.

Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res. 2001;25:553–562.CrossRefPubMed

20.

Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:60–65.CrossRef

21.

Skrabs CC. Darier sign, a historical note. Arch Dermatol. 2002;138:1253–1254.CrossRefPubMed

22.

Ray D, Williams G. Pathophysiological causes and clinical significance of flushing. Br J Hosp Med. 1993;50:594–598.PubMed

23.

Butterfield JH. Systemic mastocytosis: clinical manifestations and differential diagnosis. Immunol Allergy Clin N Am. 2006;26:487–513.CrossRef

24.

Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin N Am. 2000;14:579–623.CrossRef

25.

Cherner JA, Jensen RT, Dubois A, O’Dorisio TM, et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology. 1988;95:657–667.CrossRefPubMed

26.

Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, et al. A clinico-pathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832–843.CrossRefPubMedPubMedCentral

27.

Arguedas MR, Ferrante D. Systemic mastocytosis and giant gastroduodenal ulcer. Gastrointest Endosc. 2001;54:530–533.CrossRefPubMed

28.

Scolapio JS, Wolfe J III, Malavet P, Woodward TA. Endoscopic findings in systemic mastocytosis. Gastrointest Endosc. 1996;44:608–610.CrossRefPubMed

29.

Horny HP, Kaiserling E, Campbell M, Parwaresch MR, et al. Liver findings in generalized mastocytosis. A clinicopathologic study. Cancer. 1989;63:532–538.CrossRefPubMed

30.

Capron JP, Lebrec D, Degott C, Chivrac D, et al. Portal hypertension in systemic mastocytosis. Gastroenterology. 1978;74:595–597.CrossRefPubMed

31.

Horny HP, Metcalfe DD, Bennett JM, Bain BJ, et al. Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumors. Pathology Genetics. Tumors of haematopoietic and lymphoid tissues. Lyon, France: International agency for research on cancer; 2008:54–63.

32.

Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–232.CrossRefPubMed

33.

Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85:852–855.CrossRefPubMed

34.

Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350:735–736.CrossRefPubMed

35.

Kasamon YL, Kp CW, Subramania S, Ma L. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018;23:1511–1519.CrossRefPubMedPubMedCentral

36.

Vega-Ruiz A, Cortes JE, Sever M, Manshouri T. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33:1481–1484.CrossRefPubMedPubMedCentral

37.

Ustun C, Gotlib J, Popat U, Artz A, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transpl. 2016;22:1348–1356.CrossRef

Titel: A Granular Approach to a Patient with Diarrhea and Flushing
verfasst von: Anas Gremida
Fazia Mir
Denis McCarthy
Publikationsdatum: 20.05.2019
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 7/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-019-05673-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A Granular Approach to a Patient with Diarrhea and Flushing

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Demenzkranke durch Antipsychotika vielfach gefährdet

Drei Mythen bei der Antibiotikatherapie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Effects and Mechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier in DSS-Induced Colitis

An Operable, Portable, and Disposable Ultrathin Endoscope for Evaluation of the Upper Gastrointestinal Tract

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Analysis of Phenotypic Variables and Differentiation Between Untypical Crohn’s Disease and Untypical Intestinal Tuberculosis

Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression

Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Demenzkranke durch Antipsychotika vielfach gefährdet

Drei Mythen bei der Antibiotikatherapie

Update Innere Medizin